News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synexus Delivers Fast Phase II Study Patients for Creabilis Therapeutics


5/16/2011 10:00:40 AM

MANCHESTER, England--(BUSINESS WIRE)--Synexus has completed a phase II study for the European biotech, Creabilis, recruiting 26 patients in the UK to the psoriasis trial of its CT327 lead product in just 2 weeks, as part of an international proof-of-concept study. The company delivered the targeted number of patients well within the agreed timelines and budget.

Read at BioSpace.com

comments powered by Disqus
   
Psoriasis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES